Reuters logo
BRIEF-Loxo Oncology announces positive results from independent review committee assessment of larotrectinib dataset
2017年10月18日 / 上午10点19分 / 1 个月前

BRIEF-Loxo Oncology announces positive results from independent review committee assessment of larotrectinib dataset

Oct 18 (Reuters) - Loxo Oncology Inc

* Loxo Oncology announces positive top-line results from independent review committee assessment of larotrectinib dataset

* Loxo Oncology Inc - ‍75% overall response rate by independent review; 80% overall response rate by investigator assessment​

* Loxo Oncology Inc - ‍larotrectinib adverse event profile is consistent with data previously presented publicly

* Loxo Oncology - ‍consistent with prior guidance, co expects to submit NDA for evaluation by U.S. FDA in late 2017 or early 2018​

* Loxo Oncology - expects to submit marketing authorisation application for evaluation of larotrectinib dataset​ by EMA in 2018 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below